Developing Topics.

Background: We reviewed the data of past failures to determine how aducanumab and lecanemab might differ from the rest of this class of drugs. Specifically, whether the differences between treatment and placebo are different.

Method: We systematically analyzed the data in publications where treatments were an anti-Aβ monoclonal antibody drug, and data were available from published clinical trials.

Developing Topics.

Background: NA-831 is a candidate for the treatment of Alzheimer's Disease (AD). NA-911 is an analog of NA-831, serving as an IGF-1 and GLP-1 agonists. Animal studies of NA-911 are evaluated for the treatment of by hypoxic-ischemic injury, hemorrhagic stroke, and chronic neurodegenerative disorders METHOD: For NA-831: A randomized clinical trial of NA-831 was performed in 112 participants with mild and moderate AD, half received the drugs and half received placebo.

Developing Topics.

Background: Lecanemab has been approved by the FDA for patients with early Alzheimer's disease (AD). NA-831 is an experimental drug that has showed a proof of safety and efficacy in Phase 2 clinical trial for patients with early Alzheimer's disease. AD patients are treated with a number of comedications not only to address cognitive impairment (standard-of-care) but also other comorbidities.

Developing Topics.

Background: Adult Hippocampal Neurogenesis has been shown to be involved in Major Depressive Disorder (MDD) and Alzheimer's disease (AD) pathology. NA-831 is a small drug molecule, exhibiting neuroprotection, neurogenesis and memory enhancing properties.

Method: For AD: A randomized clinical trial of NA-831 was performed in 112 participants with mild and moderate Alzheimer's disease (AD), half received the drugs and half received placebo.

Developing Topics.

Background: NA-831 is a new drug candidate, exhibiting neuroprotection, neurogenesis and memory enhancing properties for the treatment of Alzheimer's Disease (AD). NA-931 is an analog of NA-831, regulating the homeostasis of the triple: IGF-1, GLP-1 and GIP functions for obesity.

Method: A randomized clinical trial of NA-831 was performed in 112 participants with mild and moderate AD, half received the drugs and half received placebo.